Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous blood cancer. The risk stratification and treatment decisions are mainly based on recurrent genetic and molecular biologic characteristics, which represent the natural targets of targeted therapies of AML. In recent years, new targeted agents have been rapidly developed. However, the majority of existed targeted agents have been failed to show survival improvement in multicenter randomized clinical trials. Drugs with promising effects on overall survival (OS) or event-free survival (EFS) mainly comprise all-trans retinoic acid, arsenic trioxide, midostaurin, enasidenib, decitabine, azacitidine and gemtuzumab. This article reviews the necessity, limitations and development of targeted therapy for AML and the agents which have the potential to improve the prognosis of AML. Key words: Leukemia, myeloid, acute; Targeted therapy; Survival
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
